Skip to main
DMRA

DMRA Stock Forecast & Price Target

DMRA Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 40%
Buy 60%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Damora Therapeutics is a pre-clinical stage biotechnology company that is focused on developing novel targeted biologics for myeloproliferative neoplasms (MPNs). The company's pipeline includes DMR-001, DMR-002, and DMR-003, which are all being developed for different subtypes of mutant calreticulin (mutCALR)-driven MPNs. With a validated target and a large underserved market, Damora's portfolio has the potential to drive significant clinical and commercial success. The company currently has sufficient cash to reach first-in-human proof of concept and potentially into Phase 3 trials. However, there are risks to consider, such as competition from Incyte's INCA033989 and other mutCALR-directed therapies, uncertainty around clinical trial design and endpoints, and financing and dilution risk. Overall, the fundamental reasons for a positive outlook on Damora Therapeutics include its potential to address a crucial medical need and its attractive valuation based on discounted cash flow analysis.

Bears say

Damora Therapeutics is currently pursuing its lead drug candidate, DMR-001, for the treatment of mutant calreticulin-driven myeloproliferative neoplasms, a market with high unmet need. However, the company's pipeline is still in early stages of development, with clinical initiation of DMR-001 not expected until 2026 and initial data not expected until mid-2027. This, combined with potential risks such as failure to demonstrate meaningful clinical improvement, IND submission delays, or manufacturing challenges, presents significant execution and timeline risks for the company. The lack of near-term revenue and ongoing development costs also add to the negative outlook.

DMRA has been analyzed by 5 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 60% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Damora Therapeutics, Inc. and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Damora Therapeutics, Inc. (DMRA) Forecast

Analysts have given DMRA a Buy based on their latest research and market trends.

According to 5 analysts, DMRA has a Buy consensus rating as of Aug 9, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $44.20, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $44.20, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Damora Therapeutics, Inc. (DMRA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.